Biomarin Pharmaceutical (BMRN) closed at $57.49 on October 29, 2026, up 2.7% from the previous close, on volume of 2,329,951 shares (30-day average 2,281,927).
Data as of October 29, 2026.
29-Oct-2026
PRNewswire (Thu, 29-Oct 8:46 AM ET)
Robert W. Baird Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TipRanks (Wed, 28-Oct 2:45 AM ET)
Market Chameleon (Mon, 26-Oct 5:18 AM ET)
PRNewswire (Mon, 26-Oct 9:01 AM ET)
PRNewswire (Fri, 9-Oct 9:05 AM ET)
BioMarin Appoints Cara Bauer as Chief People Officer
PRNewswire (Mon, 5-Oct 4:05 PM ET)
PRNewswire (Fri, 2-Oct 11:00 AM ET)
PRNewswire (Mon, 14-Sep 9:05 AM ET)
PRNewswire (Wed, 9-Sep 9:05 AM ET)
BioMarin to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 2-Sep 9:00 AM ET)
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Biomarin Pharmaceutical trades on the NASDAQ stock market under the symbol BMRN.
As of October 29, 2026, BMRN stock price climbed to $57.49 with 2,329,951 million shares trading.
BMRN has a beta of 0.37, meaning it tends to be less sensitive to market movements. BMRN has a correlation of 0.02 to the broad based SPY ETF.
BMRN has a market cap of $11.11 billion. This is considered a Large Cap stock.
Last quarter Biomarin Pharmaceutical reported $990 million in Revenue and $1.20 earnings per share. This beat revenue expectation by $59 million and exceeded earnings estimates by $.28.
In the last 3 years, BMRN traded as high as $99.56 and as low as $49.26.
The top ETF exchange traded funds that BMRN belongs to (by Net Assets): IJH, VTI, VB, VBK, XBI.
BMRN has underperformed the market in the last year with a return of +7.5%, while the SPY ETF gained +13.1%. In the last 3 month period, BMRN fell short of the market, returning -7.4%, while SPY returned +4.1%. However, in the most recent 2 weeks BMRN has outperformed the stock market by returning +4.3%, while SPY returned 0.0%.
BMRN support price is $54.92 and resistance is $57.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMRN shares will trade within this expected range on the day.
